MA53903A - Méthode de traitement de la myasthénie grave - Google Patents

Méthode de traitement de la myasthénie grave

Info

Publication number
MA53903A
MA53903A MA053903A MA53903A MA53903A MA 53903 A MA53903 A MA 53903A MA 053903 A MA053903 A MA 053903A MA 53903 A MA53903 A MA 53903A MA 53903 A MA53903 A MA 53903A
Authority
MA
Morocco
Prior art keywords
treatment method
graves
myasthenia
myasthenia graves
treatment
Prior art date
Application number
MA053903A
Other languages
English (en)
Inventor
Melissa Kaye Brock
William James Byrnes
Bernhard Heinrich Greve
Claus Peter Kiessling
Grant Langdon
Manis Elizabeth Webster
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA53903A publication Critical patent/MA53903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053903A 2018-10-16 2019-10-16 Méthode de traitement de la myasthénie grave MA53903A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16

Publications (1)

Publication Number Publication Date
MA53903A true MA53903A (fr) 2021-08-25

Family

ID=68290236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053903A MA53903A (fr) 2018-10-16 2019-10-16 Méthode de traitement de la myasthénie grave

Country Status (14)

Country Link
US (1) US20220144941A1 (fr)
EP (1) EP3866933A1 (fr)
JP (2) JP7518821B2 (fr)
KR (2) KR102916165B1 (fr)
CN (1) CN113646051A (fr)
AR (1) AR117653A1 (fr)
AU (1) AU2019361247B2 (fr)
BR (1) BR112021007092A2 (fr)
CA (1) CA3116091A1 (fr)
IL (1) IL282137A (fr)
MA (1) MA53903A (fr)
MX (1) MX2021004351A (fr)
SG (1) SG11202103801UA (fr)
WO (1) WO2020079086A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
CA3200972A1 (fr) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs methodes d'utilisation
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法
MX2023012032A (es) * 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
EP4519683A1 (fr) * 2022-05-05 2025-03-12 UCB Biopharma SRL Traitement de la myasthénie grave avec du zilucoplan
JP2025519559A (ja) * 2022-06-11 2025-06-26 インヒブルクス バイオサイエンシズ インコーポレイテッド ＦｃＲｎ結合ポリペプチド及びその使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (fr) 2002-12-03 2004-06-17 Celltech R & D Limited Dosage biologique permettant d'identifier des cellules productrices d'anticorps
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008538919A (ja) 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA2637929A1 (fr) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anticorps anti-fcrn utilises dans le traitement d'etats auto/allo-immuns
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535350B1 (fr) 2007-09-26 2018-01-24 UCB Biopharma SPRL Fusions d'anticorps à double spécificité
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
EP2453823B1 (fr) 2009-07-14 2015-05-13 WaveTec Vision Systems, Inc. Système de mesure pour chirurgie ophtalmique
WO2011030107A1 (fr) 2009-09-10 2011-03-17 Ucb Pharma S.A. Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP4241852A3 (fr) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Anticorps se liant à fcrn pour le traitement de maladies auto-immunes
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée

Also Published As

Publication number Publication date
AU2019361247A1 (en) 2021-05-27
KR20210078517A (ko) 2021-06-28
JP2024138363A (ja) 2024-10-08
EP3866933A1 (fr) 2021-08-25
AR117653A1 (es) 2021-08-25
KR20260014044A (ko) 2026-01-29
CN113646051A (zh) 2021-11-12
SG11202103801UA (en) 2021-05-28
IL282137A (en) 2021-05-31
CA3116091A1 (fr) 2020-04-23
BR112021007092A2 (pt) 2021-08-03
WO2020079086A1 (fr) 2020-04-23
AU2019361247B2 (en) 2025-06-26
JP7518821B2 (ja) 2024-07-18
JP2022512713A (ja) 2022-02-07
US20220144941A1 (en) 2022-05-12
MX2021004351A (es) 2021-05-31
KR102916165B1 (ko) 2026-01-22

Similar Documents

Publication Publication Date Title
EP3538130A4 (fr) Méthode de traitement de tumeur immunothérapeutique
IL282794A (en) Therapeutic methods
EP3813647A4 (fr) Stimulation multimodale de traitement des tremblements
EP3820461A4 (fr) Méthode de traitement du cancer
EP3843716A4 (fr) Méthode de traitement de maladie lysosomiale
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3500264A4 (fr) Méthode de traitement de l'oesophagite éosinophile
EP3463461A4 (fr) Procédés de traitement de la myasthénie grave généralisée réfractaire
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3448365A4 (fr) Méthode de traitement de la constipation
EP3781653A4 (fr) Traitement de biomasse à ph contrôlé
EP3341080A4 (fr) Méthode de traitement du cancer
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
EP3375440A4 (fr) Méthode de traitement de la mucosite
EP3862000A4 (fr) Médicament de traitement de la toux chronique
IL263440A (en) Methods for treating heterotopic ossification
MA52627A (fr) Traitement du cancer
EP3946608A4 (fr) Méthode de traitement de la mammite bovine
MA41462A (fr) Méthode de traitement de maladies
EP3852816A4 (fr) Méthodes de traitement de cancer
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3873528A4 (fr) Traitement de rasopathie
EP3393474A4 (fr) Méthode de traitement de l'ossification hétérotopique